GlassScriptPhysician profile
H Jedidiah Duensing
NPI 1740542232
$3,039.19
in general payments reported to CMS, 2019-2025
29 companies · $82.84 in 2025
The $82.84 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $479 · 2021: $625 · 2022: $382 · 2023: $801 · 2024: $169 · 2025: $82.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $551.72 | 2019-2023 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $530.42 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $246.65 | 2019-2024 | Trintellix |
| Amgen INC. | $221.18 | 2019-2025 | Repatha, Otezla, Evenity |
| Amarin Pharma, INC. | $191.07 | 2019-2021 | |
| Pfizer INC. | $177.95 | 2021-2024 | |
| Abbvie INC. | $170.32 | 2022-2024 | Ubrelvy, Vraylar, Qulipta |
| Abbott Laboratories | $117.86 | 2022-2023 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.28 | 2019-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $94.26 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $69.50 | 2019-2020 | |
| Gilead Sciences, INC. | $63.82 | 2023 | |
| Lilly USA, LLC | $57.45 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $48.20 | 2023 | Rexulti |
| Exact Sciences Corporation | $47.72 | 2023 | Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $47.13 | 2020 | |
| Total Joint Orthopedics, INC. | $32.90 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.93 | 2020-2021 | |
| Alkermes, INC. | $31.10 | 2023 | Vivitrol |
| Sanofi-Aventis U.S. LLC | $28.11 | 2019 | |
| Allergan, INC. | $27.53 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $24.01 | 2019-2021 | |
| Radius Health, INC. | $20.30 | 2019 | |
| Genentech USA, INC. | $20.03 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $19.04 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.45 | 2021 | |
| Shire North American Group INC | $17.33 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.70 | 2024 | Eliquis |
| Currax Pharmaceuticals LLC | $15.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw H Duensing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.